Cell line | Experimental model | RT dose | PD-1/PD-L1 dose | Ref. |
---|---|---|---|---|
B16-D5 (melanoma) | Mice subcutaneous | TBI 600 cGy (1 fraction) | PD-L1 mAb 20 mg/kg IP starting on day 4 then every 3–4 days +1X106 gp100 or OVA257–264 pulsed dendritic cell vaccine SC on day 4 and 11 ± 1X107 pmel T-cells (adoptive transfer) IV on day 4 after inoculation | [69] |
AT.3 (triple-negative mammary) | Mice xenograft | 12 Gy (1 fraction) or 4–5 Gy (4 fractions) | PD-1 mAb 100 μg + CD137 mAb 100 μg IP on days 0, 4, 8, and 12 of RT | [70, 71] |
GL261 (glioma) | Mice xenograft | 10 Gy (1 fraction) | PD-1 mAb 10 mg/kg IP on days 10, 12, and 14 of RT | [72] |
B16-SIY (melanoma) TUBO (mammary) | Mice subcutaneous | 25 Gy (2 fractions) 15 Gy (1 fraction) | PD-L1 mAb 200 μg IP every 3 days for 4 doses starting 3 weeks after RT | [92] |
5 T33 (myeloma)A20 (B-cell lymphoma)C1498 (leukemia) | Mice intravenous | TBI 500 cGy (1 fraction) | PD-L1 mAb 200 μg IP on days 12, 14, 17, 19, 21, 26, and 28 after inoculation | [75] |
5 T33 (myeloma) | Mice intravenous | TBI 1100 cGy (1 fraction) | HSCT on day 0 + PD-L1 mAb 200 μg IP on days 3, 5, 10, 12, 17, and 19 after HSCT ± vaccine (irradiated 5 T33 cells or 5 T33 cells transfected with empty vectors) on days 3, 10, and 17 after HSCT | [73] |
5 T33 (myeloma) | Mice intravenous | TBI 500 cGy (1 fraction) | PD-L1 mAb 200 μg IP on days 12, 14, 17, 19, 21, 26, and 28 after inoculation ± LAG-3, TIM-3, or CTLA-4 mAbs 200 μg IP on same days | [74] |
CT26 (colon 4434 (BRAFV600E-mutant melanoma)4 T1 (triple-negative mammary) | Mice subcutaneous | 10 Gy (5 fractions) | PD-1 or PD-L1 mAb 10 mg/kg IP 3 times weekly up to 3 weeks starting on day 1 of RT | [86] |
TUBO (mammary)MC38 (colon | Mice subcutaneous | 12 Gy (1 fraction) | PD-L1 mAb 200 μg IP every 3 days for 4 doses starting on day 0 or 1 of RT | [76] |
TSA (mammary) | Mice subcutaneous | 24 Gy (3 fractions) | PD-1 mAb (dose NR) starting on day 15 after inoculation and every 4 days thereafter | [77] |
B16-OVA (melanoma)RENCA (renal) | Mice subcutaneous | 15 Gy (1 fraction) | PD-1 mAb 10 mg/kg ± CTLA-4 mAb 10 mg/kg IP on days 7, 9, 11, 14, and 16 following tumor cell inoculation | [87] |
B16-OVA (melanoma)4 T1-HA (mammary) | Mice subcutaneous | 12 Gy (1 fraction) | PD-1 mAb 200 μg IP every 3 days for 3 doses starting 1 day prior to RT | [79] |
PyMT (mammary) | Mice subcutaneous | 12 Gy (1 fraction) | PD-1 mAb dose NR + single dose of CTLA-4 mAb (dose NR) 3 days prior to PD-1 and RT | [78] |
B16-F10 (melanoma) | Mice subcutaneous | 20 Gy (1 fraction) | PD-L1 mAb 200 μg + CTLA-4 mAb 200 μg IP every 3 days for 3 doses starting 5 or 9 days after inoculation | [61] |
Meer (head and neck squamous) | Mice subcutaneous | 1, 6, 10 Gy fractions | PD-L1 antibody dose NR | [82] |
Adeno-Cre viral vector (lung) | GEMM intrathoracic injection | 8.5 Gy twice daily over 2 days | PD-1 mAb 200 μg IP 3 times weekly starting 6 h after second RT dose | [81] |
MB49 (bladder) | Mice xenograft | 12 Gy (1 fraction) | PD-L1 mAb 250 μg IP twice weekly for 4 doses starting 1 day prior to RT | [84] |
MC38 (colon4 T1 (mammary) B16F10-OVA (melanoma) | Mice subcutaneous | 24 Gy (3 fractions) | PD-1 mAb ± CD137 mAb 5–10 mg/kg IP on days 13, 15, and 17 after inoculation | [83] |
4-hydroxytamoxifen induction (BRAF-mutant, PTEN-deficient melanoma) | GEMM topical induction | 14 Gy (1 fraction) | PD-1 + CD137 or PD-1 + CTLA-4 mAb 100 μg IP twice weekly for 4 doses on day 1 of RT | [99] |
344SQ (lung) | Mice subcutaneous | 36 Gy (3 fractions) | PD-1 mAb 10 mg/kg IP starting on day 1 of RT and continued for additional 3–4 doses | [91] |
ARK (esophageal squamous) | Mice subcutaneous | 20 Gy (10 fractions) | PD-1 mAb (dose NR) starting 2 days before RT and every 3 days thereafter ± carboplatin and paclitaxel IP (dose NR) on day 1 of RT and every 3 fractions | [85] |
GL261 (glioma) | Mice xenograft | 10 Gy (1 fraction) | PD-1 mAb 200 μg IP on days 10, 12, and 14 of RT ± TIM-3 mAb 250 μg IP days 7, 11, and 15 of RT | [90] |
CT26 (colon 4434 (BRAFV600E-mutant melanoma) | Mice subcutaneous | 10 Gy (5 fractions) | PD-1 or PD-L1 mAb 10 mg/kg IP 3 times weekly for 1 week starting on day 1 of RT | [88] |
TSA (mammary) | Mice subcutaneous | 24 Gy (3 fractions) on days 12, 13 and 14 after inoculation | PD-1 mAb 200 μg IP on days 12, 15, 19, 22 and 26 after inoculation | [89] |
Hep-55.1c (hepatocellular) | Mice orthotopic | 30 Gy (3 fractions) | PD-1 mAb 250 μg IP on days 7, 14, and 21 after inoculation | [96] |
KPC and Pan02 (pancreatic) | Mice subcutaneous | 6, 12, or 20 Gy (1 fraction)10 Gy (5 fractions)15 Gy (5 fractions) | PD-L1 mAb 10 mg/kg IP on days 4, 7, 10, and 13 after inoculation + gemcitabine 100 mg/kg IP on days 0 and 3 of inoculation | [95] |
HCa-1 (hepatocellular) | Mice intramuscular | 10 Gy (1 fraction) | PD-L1 mAb 10 mg/kg IP every 3 days for 4 doses starting on day 1 of RT | [97] |
LM8 (osteosarcoma) | Mice subcutaneous | 10 Gy (1 fraction) | PD-L1 mAb 150 μg + CTLA-4 mAb 150 μg IP every 3 days for 3 doses starting on days 9, 12, and 15 after inoculation | [98] |
CT26 (colon | Mice intradermal | RFA 17-gauge single ablation electrode for 3.5–4.5 min at target temperature of 70 degrees C | PD-1 mAb 200 μg IP every 3 days for 4 doses | [94] |
RT radiation therapy, TBI total body irradiation, cGy centigray mAb monoclonal antibody, IP intraperitoneal, SC subcutaneous, IV intravenous, Gy Gray, HSCT hematopoietic stem cell transplantation, LAG-3 lymphocyte-activation gene 3, TIM-3 T-cell immunoglobulin mucin-3, NR not reported, GEMM genetically engineered mouse model, RFA radiofrequency ablation